MARKET

VYNT

VYNT

Vyant Bio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6650
+0.0029
+0.44%
Closed 16:00 05/20 EDT
OPEN
0.6587
PREV CLOSE
0.6621
HIGH
0.7000
LOW
0.6550
VOLUME
28.40K
TURNOVER
9.74K
52 WEEK HIGH
4.235
52 WEEK LOW
0.6400
MARKET CAP
19.56M
P/E (TTM)
-0.8096
1D
5D
1M
3M
1Y
5Y
Vyant Bio to Present at the H.C. Wainwright Global Investment Hybrid Conference
Cherry Hill, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT), is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s c...
GlobeNewswire · 3d ago
--HC Wainwright Trims Vyant Bio's Price Target to $3 From $4, Buy Rating Kept
MT Newswires · 5d ago
Vyant Bio GAAP EPS of -$0.32 misses by $0.16, revenue of $0.31M beats by $0.01M
Vyant Bio press release (NASDAQ:VYNT): Q1 GAAP EPS of -$0.32 misses by $0.16. Revenue of $0.31M (+47.6% Y/Y) beats by $0.01M.
Seekingalpha · 5d ago
Vyant Bio GAAP EPS of -$0.32 misses by $0.16, revenue of $0.3M in-line
Vyant Bio press release (NASDAQ:VYNT): Q1 GAAP EPS of -$0.32 misses by $0.16. Revenue of $0.3M (+200.0% Y/Y) in-line. Shares +1.72% PM.
Seekingalpha · 6d ago
BRIEF-Vyant Bio Reports First Quarter 2022 Results And Provides Strategic And Business Highlights
reuters.com · 6d ago
-- Earnings Flash (VYNT) VYANT BIO Posts Q1 Revenue $303,000
MT Newswires · 6d ago
Notable earnings after Monday's close
ADMP, ALBO, ANY, AREC, ASTS, AXDX, CCSI, OTCQX:CWBHF, CWBR, CYRN, DAC, DADA, DNA, EGLX, FTK, FUV, GAN, GLBE, GNLN, HYRE, INPX, IONQ, IPWR, ISUN, IZEA, KBNT, KULR, MARK, MVST, OTCQB:NEXCF,
Seekingalpha · 6d ago
Vyant Bio Announces Investor Conference Call and Webcast for the First Quarter 2022
CHERRY HILL, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s cent...
GlobeNewswire · 05/10 20:01
More
No Data
Learn about the latest financial forecast of VYNT. Analyze the recent business situations of Vyant Bio Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VYNT stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.
High3.000
Average3.000
Low3.000
Current 0.6650
EPS
Actual
Estimate
-0.26-0.19-0.13-0.06
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 41
Institutional Holdings: 4.97M
% Owned: 16.91%
Shares Outstanding: 29.41M
TypeInstitutionsShares
Increased
5
34.54K
New
4
56.00K
Decreased
6
227.25K
Sold Out
6
339.73K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.64%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
John Fletcher
President/Chief Executive Officer/Director
John Roberts
Chief Financial Officer
Andrew LaFrence
Corporate Executive
Ralf Brandt
Senior Vice President
Barb Jones
Director
Marcus Boehm
Director
Paul Hansen
Director
Joanna Horobin
Director
Yung-Ping Yeh
Independent Director
Geoffrey Harris
Independent Director
Howard McLeod
No Data
No Data
About VYNT
Vyant Bio, Inc., formerly Cancer Genetics, Inc., is a biotechnology drug discovery company. The Company is engaged in identifying molecule therapeutics and decision making through in silico, in vitro, and in vivo modalities. It offers AnalytiX platform, which analyzes functional data to identify the drug candidates, targets, and biomarkers via a rank order approach. Its microOrgan technology uses functional microtissues engineered from induced pluripotent stem cells (iPSC) to facilitate human-based drug discovery. It operates two subsidiaries, vivoPharm, Pty Ltd. (vivoPharm) and StemoniX, Inc. (StemoniX). Its subsidiary, vivoPharm, offers preclinical test systems supporting clinical diagnostic offerings at early stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers. The StemoniX develops and manufactures human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development.

Webull offers kinds of Vyant Bio Inc stock information, including NASDAQ:VYNT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYNT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VYNT stock methods without spending real money on the virtual paper trading platform.